Nicotine
- Half-Life (t½)
- PO: 4.3h · SL: 2h · TD: 4.5h · INH: 4.3h
- Formula
- C10H14N2
- Molecular Weight
- 162.23 g/mol
Pharmacological Mechanism
nicotinic ach receptor pharmacology agonist (α4β2, α7); releases acetylcholine, dopamine, norepinephrine.
Half-Life & Elimination Curve (PO: 4.3h · SL: 2h · TD: 4.5h · INH: 4.3h)
Plasma (PO)t½ Decay (4.3h)Effect Site (ke0)
- 0×t½0h100% (2.41 µg/L)
- 1×t½4.3h50% (1.2 µg/L)
- 2×t½8.6h25% (0.602 µg/L)
- 3×t½12.9h12.5% (0.301 µg/L)
- 4×t½17.2h6.3% (0.15 µg/L)
- 5×t½21.5h3.1% (0.0752 µg/L)
Dosing Guidelines
- Oral (PO): Typical 2 mg (Range: 1–4 mg)
- Sublingual (SL): Typical 2 mg (Range: 1–4 mg)
- Transdermal (TD): Typical 14 mg (Range: 7–21 mg)
- Inhaled (INH): Typical 1 mg (Range: 0.5–2 mg)
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 40% · Volume of Distribution (Vd): 180 L · Absorption (ka): 0.4 h⁻¹ (t½ka ≈ 1.73h) [PMID 10583017]
- Transdermal (TD): Bioavailability (F): 76% · Volume of Distribution (Vd): 180 L [PMID 33354734]
- Inhaled (INH): Bioavailability (F): 53% · Volume of Distribution (Vd): 180 L · Absorption (ka): 10.63 h⁻¹ (t½ka ≈ 4m) [PMID 8612383]
- Effect-Site Equilibration (ke0): 3 h⁻¹ (equilibration half-time t½ke0 ≈ 14m) [PMID 9882698]
Receptor Binding & Occupancy
Pathways It Modulates
Target Organ Systems
Notes
High addiction liability. Avoid nightly use.
Chemical Structure & Identifiers
- InChIKey: SNICXCGAKADSCV-JTQLQIEISA-N
- SMILES: CN1CCC[C@H]1C2=CN=CC=C2
References